ERAS

8-K - Erasca, Inc. (0001761918) (Filer)

Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X pancreatic cancer Three potentially registration-enabling trials planned across pancreatic and lung cancers Additional Phase 1 monotherapy and combination data expected in H1 2027 SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ERAS-0015 for the treatment of patients with metastatic panc

144 - Erasca, Inc. (0001761918) (Subject)

4 - Erasca, Inc. (0001761918) (Issuer)

3 - Erasca, Inc. (0001761918) (Issuer)

S-8 - Erasca, Inc. (0001761918) (Filer)

10-Q - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination ERAS-0015 program advancing toward three potentially registration-enabling trials in pancreatic and lung cancers Additional ERAS-0015 monotherapy and combination data expected in H1 2027; ERAS-4001 Phase 1 preliminary monotherapy data expected in H2 2026 Cash, cash equivalents, and marketable securities of $384 million as of June 30, 2026; further strengthened balance sheet with upsized public offering of $632 million in July SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NA

8-K - Erasca, Inc. (0001761918) (Filer)

SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that, in connection with the appointment of Charles S. Fuchs, M.D., M.P.H., as president of research and development, Erasca’s Board of Directors has approved the grant of inducement awards. The Board of Directors approved the grant to Dr. Fuchs of non-qualified stock options to purchase 1,278,520 shares of Erasca common stock under the company’s 2026 Employment Inducement Incentive Award Plan (the "Inducement Plan"), 25% of which w

SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Charles S. Fuchs, M.D., M.P.H., as president of research and development (R&D), effective immediately. Dr. Fuchs brings more than three decades of leadership in oncology, with deep expertise across drug development, scientific innovation, and patient care. "Charlie is one of the most respected leaders in oncology, whose work has led to the successful development of multiple approved cancer therapies," said Jonatha

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 36,142,857 shares of its common stock, including 4,714,285 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $17.50 per share. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other off

8-K - Erasca, Inc. (0001761918) (Filer)

424B5 - Erasca, Inc. (0001761918) (Filer)

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 31,428,572 shares of its common stock. The shares of common stock are being sold to the public at a price of $17.50 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $

424B5 - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell, subject to market and other conditions, $500.0 million of shares of its common stock in a proposed underwritten public offering. All of the shares of common stock to be sold in the proposed offering are being offered by Erasca. In addition, Erasca intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock. There can be no assurance a

S-3ASR - Erasca, Inc. (0001761918) (Filer)

At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated at RDEs Promising combination potential, including no DLTs, encouraging safety data, and clearance of first dose escalation combination cohort of ERAS-0015 (16 mg) with approved commercial dose of panitumumab Additional ERAS-0015 monotherapy and combination data expected H1 2027, including panitumumab combination data Company plans to initiate a potentially registration-enabling trial in lung cancer in H1 2027, a Phase 3 trial in pancreatic cancer in 2027, and an additional Phase 3 tri

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)